Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

Cholangiocarcinoma is the second most common primary liver cancer. Its incidence is low in
the Western world but is rising globally. Surgery, chemotherapy and radiation therapy have …

Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a
formidable challenge due to its immunosuppressive microenvironment, thereby confounding …

The tumour microenvironment possesses mechanisms that suppress anti-tumour immunity.
Itaconate is a metabolite produced from the Krebs cycle intermediate cis-aconitate by the …

Glioblastoma (GBM) is one of the deadliest types of cancer and highly refractory to
chemoradiation and immunotherapy. One of the main reasons for this resistance to therapy …

Glioblastoma (GBM) is an aggressive primary brain cancer, with a 5 year survival of∼ 5%.
Challenges that hamper GBM therapeutic efficacy include (i) tumor heterogeneity,(ii) …

Glioblastoma (GBM) is the most belligerent and frequent brain tumor in adults. Research
over the past two decades has provided increased knowledge of the genomic and molecular …

Epigenetic lesions that disrupt regulatory elements represent potential cancer drivers.
However, we lack experimental models for validating their tumorigenic impact. Here, we …

Epigenetic remodeling is a molecular hallmark of gliomas, and it has been identified as a
key mediator of glioma progression. Epigenetic dysregulation contributes to gliomagenesis …

Tumor-associated neutrophil (TAN) effects on glioblastoma (GBM) biology remain under-
characterized. We show here that neutrophils with dendritic features—including …